Edgewise Therapeutics, Inc. Stock Price, News & Analysis

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) announced that its senior management will participate in two upcoming investor conferences:

• Jefferies Healthcare Conference: Presentation on June 10, 2022, at 10 am ET.
• Goldman Sachs Annual Global Healthcare Conference: Fireside chat on June 15, 2022, at 4 pm PT (7 pm ET).

Both events will be webcast live and available for replay. Edgewise focuses on developing therapies for rare muscle disorders using a proprietary drug discovery platform.

Edgewise Therapeutics (EWTX) announced significant progress, having completed enrollment in the ARCH study for EDG-5506 targeting Becker muscular dystrophy (BMD). A Natural History Trial for BMD has commenced, aiming to recruit around 150 participants. The company reported a net loss of $14.7 million or $0.30 per share for Q1 2022, with cash reserves of $265.8 million expected to sustain operations through 2024. Phase 2 trials for BMD and Duchenne muscular dystrophy (DMD) are planned for 2022, with interim data from the ARCH study anticipated in Q2 2022.

Edgewise Therapeutics (NASDAQ: EWTX), a clinical-stage biopharmaceutical company, will participate in two upcoming investor conferences. The BofA Securities 2022 Healthcare Conference fireside chat is scheduled for May 10, 2022, at 8:40 am PT. The RBC Capital Markets Global Healthcare Conference fireside chat will occur on May 18, 2022, at 3:35 pm ET. Presentations will be webcast live and available for replay on Edgewise’s events page.

Edgewise Therapeutics (NASDAQ: EWTX) has launched a funded observational trial to study Becker Muscular Dystrophy (BMD) progression. Led by the GRASP consortium and Virginia Commonwealth University, the two-year study aims to recruit around 150 participants aged 8 and older across the U.S. and Europe. The trial will collect data to enhance understanding of BMD, which currently has no approved therapies in the U.S. Edgewise's lead candidate, EDG-5506, has received Fast Track designation and is anticipated to enter Phase 2 trials for BMD in 2022.

Edgewise Therapeutics (NASDAQ: EWTX) announced its participation in the Muscular Dystrophy Association Annual Conference from March 13-16, 2022, in Nashville, TN. The company will present its investigational therapy EDG-5506, aimed at protecting skeletal muscle fibers in dystrophinopathies. Key presentations include a platform session led by Alan Russell and a podium presentation by Joanne Donovan. Additionally, Edgewise will host a symposium on March 14, featuring expert Luca Bello.

Edgewise Therapeutics (EWTX) announced positive topline results from the EDG-5506 Phase 1b clinical trial for Becker muscular dystrophy (BMD). The trial demonstrated safety and significant reductions in muscle damage biomarkers, including 71% reduction in creatine kinase and 83% in troponin levels. The company plans to initiate Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD) in 2022. As of December 31, 2021, Edgewise had $281 million in cash and equivalents. For 2021, R&D expenses totaled $32.2 million, contributing to a net loss of $42.8 million.

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) announced its participation in the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 16, 2022. Senior management will engage in a fireside chat at 12 pm ET, which will be webcast live and available for replay. The company specializes in developing small molecule therapies for rare muscle disorders, utilizing a unique drug discovery platform aimed at treating severe neuromuscular and cardiac conditions. More details can be found on their website.

Edgewise Therapeutics (NASDAQ: EWTX) announced positive topline results from the Phase 1b clinical trial of EDG-5506, targeting Becker Muscular Dystrophy (BMD). The treatment was well-tolerated, with no serious adverse events reported. Notably, EDG-5506 significantly reduced muscle damage biomarkers, including creatine kinase (CK) by 71% and fast skeletal muscle troponin (TNNI2) by 83%. These findings suggest the drug's potential in preserving muscle function. Management will discuss these results in a webcast at 9:00 a.m. ET today.

Edgewise Therapeutics (NASDAQ: EWTX) plans to announce topline results from the Phase 1b clinical trial of EDG-5506 for Becker muscular dystrophy (BMD) on January 5, 2022. The event will feature expert commentary and details about the new open-label study ARCH. The trial has enrolled 7 participants and assessed a 20 mg dose for 14 days, focusing on safety and biomarkers for muscle damage. A follow-up Phase 2 clinical trial is anticipated to begin in the first half of 2022 for BMD and later in the year for Duchenne muscular dystrophy (DMD).